TransMedics Group, Inc.TMDXNASDAQ
Loading
TMDX Revenue Growth (YoY Quarterly)•+32.18%
Stock Alarm Pro
Growth Metrics
Latest: Q4 2025vs Q3 2025
Revenue GrowthGross Profit GrowthEBITDA GrowthOperating Income GrowthNet Income GrowthEPS GrowthEPS Diluted GrowthWeighted Average Shares GrowthWeighted Average Shares Diluted GrowthDividends per Share Growth
+32.18%
-0.1pp
+29.72%
-9.3pp
+99.85%
-56.1pp
+146.10%
-347.8pp
+1436.87%
+960.0pp
+1440.00%
+993.8pp
+1263.16%
+813.2pp
+1.87%
-0.1pp
+16.24%
+2.0pp
+0.00%
+0.0pp
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +49.83% | +48.21% | +37.68% | +32.24% | +32.18% |
| Gross Profit Growth | +50.27% | +47.39% | +39.66% | +39.00% | +29.72% |
| EBITDA Growth | +46.66% | +77.87% | +127.68% | +155.93% | +99.85% |
| Operating Income Growth | +232.08% | +120.94% | +192.35% | +493.93% | +146.10% |
| Net Income Growth | +70.11% | +110.56% | +186.26% | +476.83% | +1436.87% |
| EPS Growth | +66.67% | +105.41% | +178.38% | +446.15% | +1440.00% |
| EPS Diluted Growth | +58.33% | +100.00% | +162.86% | +450.00% | +1263.16% |
| Weighted Average Shares Growth | +2.90% | +2.94% | +2.39% | +2.01% | +1.87% |
| Weighted Average Shares Diluted Growth | +3.02% | +15.10% | +14.94% | +14.19% | +16.24% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +136.79% | +0.00% | +256.21% | +914.63% | +75.52% |
| Free Cash Flow Growth | +0.00% | +0.00% | +4121.69% | +0.00% | +213.67% |
| Receivables Growth | +53.71% | +73.33% | +29.19% | -10.46% | -13.75% |
| Inventory Growth | +5.24% | -10.63% | -20.14% | -14.66% | +5.00% |
| Asset Growth | +13.88% | +15.71% | +17.39% | +20.43% | +32.87% |
| Book Value per Share Growth | +61.92% | +62.23% | +63.60% | +65.88% | +103.16% |
| Debt Growth | +0.45% | +0.42% | +0.45% | +0.23% | -9.38% |
| R&D Expense Growth | +53.00% | +50.79% | +14.98% | +6.97% | +25.73% |
| SG&A Expenses Growth | +35.72% | +20.98% | +3.02% | +7.87% | +9.67% |
1 / 4